Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 90

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 90
---
 redeeming their Public Shares and US$60,458.00 for the accrued interest thereon) would be drawn from the Trust Account. Consequently, no funds held on trust would be available to the Company. (9)The transaction costs and expenses include $5,880,759 corresponding to APx (which has a liability recorded of $2,118,948 in its statement of financial position as December 31, 2024 for this concept) and $4,490,000 corresponding to the Company (which has a liability recorded of $989,500 in its statement of financial position as of that date). Consequently, the transaction costs and expenses total $10,370,759, of which, there are liabilities recorded for $3,108,448 as of December 31, 2024 in the historical statements of financial position as of that date and $7,262,311 will be recognized in the business combination. The Company expects to apply cash and cash equivalents derived from the Business Combinations to partially settle estimated transaction costs and cancel the remaining balance through other sources of financing considering the available credit lines (according to the table above, the excess of estimated transaction costs over cash sources amounts to $366,126). Certain United States Federal Income Tax Considerations For a discussion summarizing the material United States federal income tax considerations of an exercise of Redemption Rights, please see “ Material U.S. Federal Income Tax Considerations” below. Accounting Treatment of the Business Combination OmnigenicsAI will account for the Business Combination as a capital reorganization in accordance with IFRS as issued by the IASB. Under this method of accounting, APx will be treated as the “acquired” company for financial reporting purposes and OmngenicsAI will be the accounting “acquirer.” This determination was primarily based on the assumptions that OmngenicsAI’s shareholders will hold a majority of the voting power of the Combined Company, the Combined Company’s operations will substantially comprise the ongoing operations of OmngenicsAI, OmngenicsAI’s designees are expected to comprise a majority of the governing body of the Combined Company, and OmngenicsAI’s senior management will comprise the senior management of the Combined Company. APx does not meet the definition of a “business” pursuant to IFRS3, Business Combinations, and thus, for accounting purposes, OmnigenicsAI will account for the Business Combination as a capital reorganization. The net assets of APx will be stated at historical cost, with no goodwill or other intangible